ZBED1 and plasma cell myeloma: In agreement with the gene model, compared with bortezomib-sensitive myeloma cell lines (negative control), there was an increase in mRNA expression of SCN9A, RGS7, NTF3, HSPB8, and ZBED1 and a decrease in CCND1, COBLL1, EGR1, OCLN, and ZBED1 mRNA expression of bortezomib-resistant cell lines (Figure 9).